<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906529</url>
  </required_header>
  <id_info>
    <org_study_id>Novo 092</org_study_id>
    <nct_id>NCT00906529</nct_id>
  </id_info>
  <brief_title>Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin</brief_title>
  <acronym>RASCIN</acronym>
  <official_title>RAndomized SubCutaneous Insulin in INpatients (RASCIN) Trial: Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aggressive (goal pre-prandial blood glucose&#xD;
      &lt;110 mg/dl) versus conservative (goal pre-prandial blood glucose &lt;180mg/dl) diabetes&#xD;
      treatment of type 2 diabetic patients on the general medical wards has any effect on hospital&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The objective of this study is to determine the effect of an &quot;aggressive&quot; blood&#xD;
      glucose control (goal pre-prandial CBG &lt;110 mg/dl) versus a &quot;conservative&quot; blood glucose&#xD;
      control (goal pre-prandial CBG &lt;180 mg/dl) on length of stay in hospitalized type 2 diabetic&#xD;
      patients using levemir (detemir) and novolog (aspart) insulins.&#xD;
&#xD;
      Study Site: Parkland Memorial Hospital, 5201 Harry Hines Blvd, Dallas, Texas 75235. Parkland&#xD;
      Hospital is a 720 adult bed public hospital that serves as the main teaching hospital for the&#xD;
      University of Texas-Southwestern Medical Center. In addition, Parkland Memorial Hospital&#xD;
      possesses the University Diabetes Treatment Center, an eleven bed medical ward devoted to&#xD;
      inpatient diabetes management. This study will be conducted throughout all of Parkland's&#xD;
      general medical floors, including the University Diabetes Treatment Center.&#xD;
&#xD;
      Patient Population: The population for this study includes men and women with type 2 diabetes&#xD;
      admitted to the general medicine wards of Parkland Memorial Hospital.&#xD;
&#xD;
      Study Design and Duration: This is a single-center, randomized, single blind, non-inferiority&#xD;
      study design.&#xD;
&#xD;
      Patients admitted to Parkland Hospital with type 2 diabetes will be recruited to the study&#xD;
      within 24 hours of admission. Gravid patients, patients in DKA, or HHS will be excluded. All&#xD;
      patients will be evaluated for inclusion and exclusion criteria. During the hospitalization,&#xD;
      patients will be stratified by age and admitting diagnosis and randomized to either an&#xD;
      &quot;aggressive&quot; blood glucose control (goal pre-prandial CBG &lt;110 mg/dl) or a &quot;conservative&quot;&#xD;
      blood glucose control (goal pre-prandial CBG &lt;180 mg/dl). Subcutaneous detemir and novolog&#xD;
      will be employed according to the enclosed protocol to meet the goal blood glucose level. The&#xD;
      insulin will be administered by nursing staff via the FlexPen, a pre-filled pen-like insulin&#xD;
      delivery device. CBGs will be obtained before breakfast, before lunch, before supper, and at&#xD;
      bedtime. If a patient is NPO, then the CBGs will be obtained at the time that the patient was&#xD;
      to have eaten.&#xD;
&#xD;
      Treatment of the patient's primary admitting diagnosis including plan and procedures will be&#xD;
      completely at the primary team's discretion.&#xD;
&#xD;
      Should a patient require transfer to an intensive care unit or to a telemetry unit, then the&#xD;
      patient's participation in the study will be held until discharge from said unit. While the&#xD;
      patient is in an ICU or telemetry unit, the blood glucose goal and management will be&#xD;
      completely decided upon by the primary team.&#xD;
&#xD;
      The study will terminate at the end of the hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Hospitalization Stay</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost of Hospitalization</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Hypoglycemic Episodes</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Transfer to Telemetry Unity</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Nosocomial Infections</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Procedures</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Re-hospitalization</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to goal blood glucose level</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to becoming medically stable for discharge</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Conservative Blood Glucose Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Goal Pre-prandial blood glucose &lt;180 mg/dl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive Blood Glucose Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-prandial goal blood glucose &lt;110 mg/dl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levemir (Detemir) and Novolog (Aspart) Insulin</intervention_name>
    <description>Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal</description>
    <arm_group_label>Aggressive Blood Glucose Control</arm_group_label>
    <arm_group_label>Conservative Blood Glucose Control</arm_group_label>
    <other_name>Detemir</other_name>
    <other_name>Aspart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Existing diagnosis of type 2 diabetes.&#xD;
&#xD;
          -  Admitted to a non-telemetry, non-ICU medicine inpatient bed.&#xD;
&#xD;
          -  Willing and able to give informed consent.&#xD;
&#xD;
          -  HgbA1c of any value will be accepted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Admitted to a telemetry, ICU, or non-medicine inpatient bed (e.g., surgery,&#xD;
             neurosurgery, obstetrics/gynecology, psychiatry).&#xD;
&#xD;
          -  Diabetic ketoacidosis (arterial ph &lt;7.24, serum bicarbonate &lt;15, positive serum&#xD;
             ketones, anion gap &gt;12)&#xD;
&#xD;
          -  Hyperosmolar hyperglycemic state (blood glucose &gt;200 mg/dl, serum osmolarity &gt;320&#xD;
             mOsm/kg)&#xD;
&#xD;
          -  Inability to cooperate with study personnel.&#xD;
&#xD;
          -  Known allergy or intolerance to detemir or novolog.&#xD;
&#xD;
          -  Admission to the hospital &gt;24 hours from entry into the study.&#xD;
&#xD;
          -  Admission to the hospital for inpatient hospice care.&#xD;
&#xD;
          -  Admission/continued admission to the hospital for procurement of a guardian.&#xD;
&#xD;
          -  Admission/continued admission to the hospital for rehabilitation.&#xD;
&#xD;
          -  Patients admitted with the diagnosis of acute coronary syndrome.&#xD;
&#xD;
          -  Patients admitted with the diagnosis of acute cerebrovascular accident.&#xD;
&#xD;
          -  Patients currently pregnant or breast-feeding.&#xD;
&#xD;
          -  Patients not fluent in English or Spanish as it will be difficult to obtained written&#xD;
             informed consent in another language.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Fordan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Richard, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Raskin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Memorial Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.utsouthwestern.edu/utsw/cda/dept226287/files/308724.html</url>
    <description>UT Southwestern Clinical Trials</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <name_title>Steve Fordan, MD/Principal Investigator</name_title>
    <organization>University of Texas Southwestern Medical School</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Inpatient</keyword>
  <keyword>Length of Stay</keyword>
  <keyword>Blood Glucose Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

